The Russian investment fund RFPI, which developed Sputnik V, has agreed with manufacturers from Italy, Spain, France and Germany to produce the vaccine. The agreements will facilitate its deployment in the European Union if the vaccine is approved by the European Union Medicines Authority (EMA).
The message does not mean that countries themselves bought the vaccine, confirms Swedish national vaccination coordinator Richard Bergstrom.
A lot of people seem to think it’s all about the dosage agreements. But it is a manufacturing contract between the vaccine developer and the private sector in these countries.
At the same time, he says That there are talks about producing a Sputnik vaccine in Sweden as well.
There are serious talks going on between Sputnik and some manufacturers in Sweden. I can’t say more than that, says Richard Bergstrom.
On the other hand, the availability of vaccines in Sweden will not be affected if such an agreement is concluded.
– That’s not how it works. You don’t get a vaccine because you are building a factory. If not the UK or the US, says Richard Bergstrom, he points to the countries’ export barriers, which means the European Union will receive 75 million fewer doses during the second quarter.
On the other hand, it might be a good idea to have this kind of vaccine infrastructure in place in the future.
So far, Sputnik V Approval within the European Union. Since March 4, the European Medicines Agency has been reviewing the vaccine continuously to ensure it is safe and effective. The union also did not sign an agreement with the developer, although negotiations have been going on for some time.
Richard Bergstrom previously said approval could be relevant in May or June at the earliest.
However, not many countries will wait for the agency’s approval. Hungary gave the green light to Sputnik V already in February and today it is using a vaccine. Both the Czech Republic and Slovakia have requested doses and vaccinations will begin upon the arrival of the deliveries.